Catalyst Pharmaceuticals Shares Outstanding 2006-2019 | CPRX

Catalyst Pharmaceuticals shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Catalyst Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2018 103
2017 86
2016 83
2015 81
2014 64
2013 45
2012 30
2011 22
2010 19
2009 15
2008 13
2007 13
2006 8
2005 6
Catalyst Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 103
Q4 2018 103
Q3 2018 103
Q2 2018 103
Q1 2018 103
Q4 2017 86
Q3 2017 85
Q2 2017 84
Q1 2017 83
Q4 2016 83
Q3 2016 83
Q2 2016 83
Q1 2016 83
Q4 2015 81
Q3 2015 82
Q2 2015 82
Q1 2015 76
Q4 2014 64
Q3 2014 67
Q2 2014 66
Q1 2014 54
Q4 2013 45
Q3 2013 45
Q2 2013 41
Q1 2013 41
Q4 2012 30
Q3 2012 32
Q2 2012 27
Q1 2012 25
Q4 2011 22
Q3 2011 22
Q2 2011 22
Q1 2011 20
Q4 2010 19
Q3 2010 19
Q2 2010 18
Q1 2010 18
Q4 2009 15
Q3 2009 14
Q2 2009 14
Q1 2009 14
Q4 2008 13
Q3 2008 13
Q2 2008 13
Q1 2008 13
Q4 2007 13
Q3 2007 13
Q2 2007 13
Q1 2007 13
Q4 2006 8
Q3 2006 7
Q2 2006 7
Q1 2006 7
Q3 2005 7
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.371B $0.001B
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $54.313B 34.70
Takeda Pharmaceutical (TAK) Japan $27.201B 7.99
Grifols (GRFS) Spain $13.779B 17.43
Sage Therapeutics (SAGE) United States $9.044B 0.00
Ionis Pharmaceuticals (IONS) United States $8.958B 19.58
Neurocrine Biosciences (NBIX) United States $7.714B 0.00
Catalent (CTLT) United States $7.679B 30.82
Jazz Pharmaceuticals (JAZZ) Ireland $7.437B 10.19
Nektar Therapeutics (NKTR) United States $5.907B 9.63
Tilray (TLRY) Canada $4.670B 0.00
FibroGen (FGEN) United States $3.751B 0.00
United Therapeutics (UTHR) United States $3.332B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.309B 11.61
Arrowhead Pharmaceuticals (ARWR) United States $2.607B 392.86
PTC Therapeutics (PTCT) United States $2.470B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.924B 6.92
Xencor (XNCR) United States $1.909B 52.11
Portola Pharmaceuticals (PTLA) United States $1.796B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.781B 86.24
Zogenix (ZGNX) United States $1.730B 0.00
Tricida (TCDA) United States $1.720B 0.00
USANA Health Sciences (USNA) United States $1.688B 14.67
Enanta Pharmaceuticals (ENTA) United States $1.630B 22.28
Ironwood Pharmaceuticals (IRWD) United States $1.590B 0.00
Madrigal Pharmaceuticals (MDGL) United States $1.557B 0.00
Heron Therapeutics (HRTX) United States $1.406B 0.00
Aerie Pharmaceuticals (AERI) United States $1.387B 0.00
Turning Point Therapeutics (TPTX) United States $1.322B 0.00
Esperion Therapeutics (ESPR) United States $1.309B 0.00
Corcept Therapeutics (CORT) United States $1.190B 16.98
ArQule (ARQL) United States $1.094B 0.00
Radius Health (RDUS) United States $1.078B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.916B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.899B 0.00
Endo (ENDP) Ireland $0.812B 1.31
Aptorum Group (APM) China $0.755B 0.00
Odonate Therapeutics (ODT) United States $0.751B 0.00
CannTrust Holdings (CTST) Canada $0.706B 0.00
Organogenesis Holdings (ORGO) United States $0.658B 0.00
Translate Bio (TBIO) United States $0.638B 0.00
TherapeuticsMD (TXMD) United States $0.603B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.573B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.567B 0.00
Dermira (DERM) United States $0.510B 0.00
Akebia Therapeutics (AKBA) United States $0.502B 0.00
ChemoCentryx (CCXI) United States $0.495B 0.00
GlycoMimetics (GLYC) United States $0.485B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.459B 0.00
Siga Technologies (SIGA) United States $0.450B 1.06
BioSpecifics Technologies Corp (BSTC) United States $0.420B 21.18
Flexion Therapeutics (FLXN) United States $0.414B 0.00
Collegium Pharmaceutical (COLL) United States $0.414B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.400B 0.00
Karyopharm Therapeutics (KPTI) United States $0.386B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.370B 0.00
KalVista Pharmaceuticals (KALV) United States $0.367B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.349B 0.00
TCR2 Therapeutics (TCRR) United States $0.349B 0.00
Rafael Holdings (RFL) United States $0.334B 0.00
Forty Seven (FTSV) United States $0.333B 0.00
Harpoon Therapeutics (HARP) United States $0.309B 0.00
Molecular Templates (MTEM) United States $0.299B 0.00
OptiNose (OPTN) United States $0.298B 0.00
Xeris Pharmaceuticals (XERS) United States $0.291B 0.00
CASI Pharmaceuticals (CASI) United States $0.290B 0.00
ImmunoGen (IMGN) United States $0.280B 0.00
Concert Pharmaceuticals (CNCE) United States $0.271B 0.00
Dova Pharmaceuticals (DOVA) United States $0.264B 0.00
Aratana Therapeutics (PETX) United States $0.246B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.238B 0.00
Minerva Neurosciences (NERV) United States $0.231B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.225B 0.00
Lannett Co Inc (LCI) United States $0.222B 2.15
Recro Pharma (REPH) United States $0.215B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.200B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.196B 0.00
Aldeyra Therapeutics (ALDX) United States $0.195B 0.00
Opexa Therapeutics (ACER) United States $0.194B 0.00
Bio Blast Pharma (ENLV) Israel $0.188B 0.00
Galectin Therapeutics (GALT) United States $0.187B 0.00
Ocular Therapeutix (OCUL) United States $0.187B 0.00
Aclaris Therapeutics (ACRS) United States $0.184B 0.00
MEI Pharma (MEIP) United States $0.183B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.182B 0.00
Taiwan Liposome, Unsponsored ADR (TLC) Taiwan $0.169B 0.00
Nature's Sunshine Products (NATR) United States $0.160B 51.88
Ardelyx (ARDX) United States $0.159B 0.00
Calithera Biosciences (CALA) United States $0.152B 0.00
Redhill Biopharma (RDHL) Israel $0.150B 0.00
IMV INC (IMV) Canada $0.148B 0.00
AgeX Therapeutics (AGE) United States $0.148B 0.00
Jounce Therapeutics (JNCE) United States $0.147B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.141B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.140B 0.00
Majesco Entertainment (PTE) United States $0.138B 0.00
Neon Therapeutics (NTGN) United States $0.131B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.116B 0.00
Tyme Technologies (TYME) United States $0.114B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.103B 0.00
DURECT (DRRX) United States $0.102B 0.00
Aquestive Therapeutics (AQST) United States $0.101B 0.00
Avenue Therapeutics (ATXI) United States $0.100B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.098B 70.00
Bellicum Pharmaceuticals (BLCM) United States $0.097B 0.00
China SXT Pharmaceuticals (SXTC) China $0.096B 0.00
Iterum Therapeutics (ITRM) Ireland $0.094B 0.00
Champions Oncology (CSBR) United States $0.094B 0.00
Infinity Pharmaceuticals (INFI) United States $0.092B 0.00
Mast Therapeutics (SVRA) United States $0.092B 0.00
Cardiome Pharma (CORV) Canada $0.092B 0.00
MediWound (MDWD) Israel $0.088B 0.00
Natural Alternatives (NAII) United States $0.088B 8.80
Nivalis Therapeutics (ALPN) United States $0.084B 0.00
India Globalization Capital (IGC) United States $0.081B 0.00
Capnia (SLNO) United States $0.079B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.079B 0.00
Otonomy (OTIC) United States $0.079B 0.00
Adherex Technologies (FENC) United States $0.078B 0.00
Novan (NOVN) United States $0.072B 0.00
Melinta Therapeutics (MLNT) United States $0.069B 0.00
SCYNEXIS (SCYX) United States $0.069B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.060B 0.00
Neos Therapeutics (NEOS) United States $0.058B 0.00
CTI BioPharma (CTIC) United States $0.056B 0.00
ElectroCore (ECOR) United States $0.056B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.055B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.054B 0.00
Genocea Biosciences (GNCA) United States $0.051B 0.00
Zafgen (ZFGN) United States $0.049B 0.00
ProNAi Therapeutics (SRRA) Canada $0.046B 0.00
AIT Therapeutics (AITB) Israel $0.046B 0.00
Forward Pharma (FWP) Denmark $0.046B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.045B 0.00
KemPharm (KMPH) United States $0.044B 0.00
Lipocine (LPCN) United States $0.043B 0.00
BioLineRx (BLRX) Israel $0.043B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.042B 0.00
Mannatechorporated (MTEX) United States $0.040B 0.00
ContraFect (CFRX) United States $0.039B 0.00
Bio-Path Holdings (BPTH) United States $0.037B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.035B 0.00
ProPhase Labs (PRPH) United States $0.033B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.032B 0.00
PharmAthene (ALT) United States $0.030B 0.00
IsoRay (ISR) United States $0.028B 0.00
Heat Biologics (HTBX) United States $0.025B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.025B 0.00
Regulus Therapeutics (RGLS) United States $0.025B 0.00
GTx (ONCT) United States $0.025B 0.00
Biomerica (BMRA) United States $0.024B 0.00
Pain Therapeutics (SAVA) United States $0.023B 0.00
Citius Pharmaceuticals (CTXR) United States $0.023B 0.00
Onconova Therapeutics (ONTX) United States $0.022B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.020B 1.64
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.019B 0.00
Cyanotech (CYAN) United States $0.018B 0.00
NanoViricides (NNVC) United States $0.018B 0.00
Shineco (TYHT) China $0.016B 0.00
Achieve Life Sciences (ACHV) United States $0.014B 0.00
ESSA Pharma (EPIX) Canada $0.014B 0.00
HANCOCK JAFFE (HJLI) United States $0.014B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.013B 0.00
VAXART, INC (VXRT) United States $0.012B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.011B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.011B 1.81
Ohr Pharmaceuticals (OHRP) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Trillium Therapeutics (TRIL) Canada $0.010B 0.00
RXi Pharmaceuticals (PHIO) United States $0.009B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.008B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
Jaguar Animal Health (JAGX) United States $0.007B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.004B 0.00
Can-Fite Biopharma (CANF) Israel $0.004B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00